To include your compound in the COVID-19 Resource Center, submit it here.

Exenatide once monthly: Additional Phase II data

Additional data from an open-label, U.S. Phase II trial in 121 Type II diabetics showed that 50%, 57% and 70% of patients receiving 5, 8 and 11 mg subcutaneous exenatide once monthly, respectively, achieved

Read the full 341 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE